Stewart A, Eyers P S, Earnshaw J J
Dolphin House, Department of Vascular Surgery, Bristol Royal Infirmary, Bristol, UK BS2 8HW.
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD003073. doi: 10.1002/14651858.CD003073.pub2.
Arterial reconstructions with prosthetic graft materials or vein are susceptible to infection with a resultant high patient mortality and risk of limb loss. To reduce the risk of infection effective perioperative measures are essential.
To determine the effectiveness of perioperative strategies to prevent infection in patients undergoing peripheral arterial reconstruction.
We searched the Cochrane Peripheral Vascular Diseases Group trials register (last searched May 2006) and the Cochrane Central Register of Controlled Trials (CENTRAL) (last searched Issue 2, 2006), and reference lists of relevant articles.
All randomised controlled trials (RCTs) evaluating measures intended to reduce or prevent infection in arterial surgery.
AS and PSE independently selected and assessed the quality of included trials. Relative risk was used as a measure of effect for each dichotomous outcome.
Thirty-five RCTs were included. Of these, 23 were trials of prophylactic systemic antibiotics, three of rifampicin-bonded grafts, three of preoperative skin antisepsis, two of suction wound drainage, two of minimally invasive in situ bypass techniques, and individual trials of intraoperative glove change and wound closure techniques. Wound infection or early graft infection outcomes were recorded in all trials. Only two trials, both of rifampicin bonding, followed up graft infection outcomes to two years. Trials of antibiotics versus placebo were of highest quality with six double-blind studies of the ten included. Prophylactic systemic antibiotics reduced the risk of wound infection (Relative Risk (RR) 0.25, 95% Confidence Interval (CI) 0.17 to 0.38) and early graft infection in a fixed-effect model (RR 0.31, 95% CI 0.11 to 0.85, P = 0.02). Antibiotic prophylaxis for greater than 24 hours appears to be of no added benefit (RR 1.28, 95% CI 0.82 to 1.98). There was no evidence that prophylactic rifampicin bonding to dacron grafts reduced graft infection at either one month (RR 0.63, 95% CI 0.27 to 1.49) or two years (RR 1.05, 95% CI 0.46 to 2.40). There was no evidence of a beneficial or detrimental effect on rates of wound infection with suction groin-wound drainage (RR 0.96 95% CI 0.50 to 1.86) or of any benefit from a preoperative bathing or shower regimen with antiseptic agents over unmedicated bathing (RR 0.97, 95% CI 0.70 to 1.36).
AUTHORS' CONCLUSIONS: There is clear evidence of the benefits of prophylactic broad spectrum antibiotics. Many other interventions intended to reduce the risk of infection in arterial reconstruction lack evidence of effectiveness.
使用人工血管材料或静脉进行动脉重建易发生感染,导致患者死亡率高且有肢体丧失风险。采取有效的围手术期措施对于降低感染风险至关重要。
确定围手术期策略预防接受外周动脉重建患者感染的有效性。
我们检索了Cochrane外周血管疾病组试验注册库(最近检索时间为2006年5月)和Cochrane对照试验中心注册库(CENTRAL)(最近检索时间为2006年第2期)以及相关文章的参考文献列表。
所有评估旨在减少或预防动脉手术感染措施的随机对照试验(RCT)。
AS和PSE独立选择并评估纳入试验的质量。相对风险用作每个二分结果的效应量度。
纳入了35项RCT。其中,23项是预防性全身抗生素试验,3项是利福平涂层移植物试验,3项是术前皮肤消毒试验,2项是负压伤口引流试验,2项是微创原位旁路技术试验,以及术中更换手套和伤口闭合技术的个别试验。所有试验均记录了伤口感染或早期移植物感染结果。只有两项试验,均为利福平涂层试验,对移植物感染结果随访至两年。抗生素与安慰剂试验质量最高,纳入的10项中有6项双盲研究。预防性全身抗生素在固定效应模型中降低了伤口感染风险(相对风险(RR)0.25,95%置信区间(CI)0.17至0.38)和早期移植物感染风险(RR 0.31,95%CI 0.11至0.85,P = 0.02)。抗生素预防超过24小时似乎没有额外益处(RR 1.28,95%CI 0.82至1.98)。没有证据表明利福平与涤纶移植物结合在1个月(RR 0.63,95%CI 0.27至1.49)或两年(RR 1.05,95%CI 0.46至2.40)时能降低移植物感染风险。没有证据表明腹股沟伤口负压引流对伤口感染率有有益或有害影响(RR 0.96,95%CI 0.50至1.86),也没有证据表明术前使用抗菌剂沐浴或淋浴方案比未使用药物的沐浴有任何益处(RR 0.97,95%CI 0.70至1.36)。
有明确证据表明预防性广谱抗生素有益。许多其他旨在降低动脉重建感染风险的干预措施缺乏有效性证据。